CRISPR Therapeutics

CRISPR Therapeutics, Casebia Therapeutics partner with StrideBio

Tuesday, April 18, 2017

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer for developing CRISPR-based therapeutics in select disease areas, have signed a collaboration agreement with StrideBio, a U.S.-based company developing novel AAV vectors for in vivo gene delivery applications.

[Read More]

CRISPR/Cas9 U.S. patent board decision appealed

Friday, April 14, 2017

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics announced that The Regents of the University of California, the University of Vienna and Dr. Emmanuelle Charpentier (collectively UC), co-owners of foundational intellectual property relating to CRISPR/Cas9 genome engineering, have appealed to the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit) the decision by the Patent Trial and Appeal Board (PTAB) to terminate the interference between certain CRISPR/Cas9 patent claims owned by UC and patents and patent applications owned by the Broad Institute, Harvard University and the Massachusetts Institute of Technology (collectively Broad).

[Read More]

CRISPR, Intellia, Caribou and ERS Genomics provide update on CRISPR/Cas9 U.S. patent

Friday, February 17, 2017

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics provided an update on the Patent Trial & Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) decision on the motions filed by the University of California, the University of Vienna and Dr. Emmanuelle Charpentier (collectively, UC), on one hand, and the Broad Institute, Harvard University and the Massachusetts Institute of Technology (collectively, Broad), on the other, in the interference proceeding relating to CRISPR/Cas9 genome editing technology.

[Read More]

Casebia Therapeutics establishes operations in Cambridge, Massachusetts

Tuesday, August 23, 2016

Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, Massachusetts. In December, 2015 Bayer and CRISPR Therapeutics agreed to create a joint venture to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness and congenital heart disease. The two parties formally closed the transaction in the first quarter of 2016.

[Read More]

ERT opening Innovation Lab in Boston

Monday, February 8, 2016

ERT is launching an Innovation Lab in Boston on February 9. A cloud platform solutions provider, ERT supplies the industry, sponsors and CROs alike, with technology, services and consultancy. The company is known for first-in-the-industry features such as wireless eDiaries to collect electronic Clinical Outcome Assessments (eCOA).

[Read More]

Mass Innovation Labs may spur partnerships

Monday, January 11, 2016

Mass Innovation Labs, an accelerated commercialization space, has signed 10 member companies since opening its doors in May 2015, including CRISPR Therapeutics, Imagen Biopharma, Gritstone Oncology, WaveGuide, Radius Health, TCR2 and Editas. Mass Innovation Labs’ member companies account for more than $1 billion in startup R&D capital in one location, and have achieved many important milestones after receiving operational support through the Jumpstart program.

[Read More]